601136 Capital
- 19.64
- +0.20+1.03%
Capital News
Capital Securities (601136): Self-operated business flexibility and other business resilience highlighted
Capital Securities (601136): Continuously consolidating advantages, business development path is progressing steadily
Capital Securities (601136) 23Q1 review: Proprietary income rebounded sharply, net asset management income declined
First coverage of Capital Securities (601136): steady development of fixed income business, rise of asset management drives performance
Catalyst Biosciences (CBIO) Gets a Buy From LifeSci Capital
Gesher I Corp (GIAC) Receives a New Rating From Chardan Capital
Chardan Capital Initiates Coverage On Century Therapeutics With Buy Rating, Announces Price Target of $19
Chardan Capital Initiates Coverage On Gesher I Acquisition With Buy Rating, Announces Price Target of $13
CarMax (KMX) Gets a Buy From RBC Capital
RBC Capital Remains a Buy on Citizens Financial (CFG)
RBC Capital Keeps Their Buy Rating on Spirit AeroSystems (SPR)
Silgan Holdings (SLGN) Gets a Buy From RBC Capital
Ardagh Metal Packaging (AMBP) Receives a Hold From RBC Capital
RBC Capital Sticks to Its Buy Rating for Xylem (XYL)
RBC Capital Sticks to Its Hold Rating for CareTrust REIT (CTRE)
KeyCorp (KEY) Receives a Buy From RBC Capital
Roth Capital Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $90
Loop Capital Downgrades Paramount Global to Sell From Hold, Cuts Price Target to $14 From $30
Daiwa Capital Initiates Enphase Energy With Outperform Rating, $335 Price Target
Chardan Capital Initiates Coverage On Anixa Biosciences With Buy Rating, Announces Price Target of $8
Analysis
Price Target
No Data
